OpenEye, Cadence Molecular Sciences has partnered with Opportunity Pharma, an early-stage SaaS company, to build an artificial intelligence (AI) virtual expert for drug discovery investors.
Opportunity Pharma is using OpenEye computational drug discovery software as part of its development of the virtual expert.
Opportunity Pharma’s virtual expert will access a scientifically curated database of investable opportunities including disease areas, drug targets, and drug-like molecules. This will enable venture capital firms to create curated and objective comparisons of new drug discovery investment opportunities, and ultimately lead to more new high-quality medicine. The first version of the virtual expert is expected in 2024.